A 2026 study in BMC Pharmacology and Toxicology reported that CYP3A5 genetic variability can be used to tailor tacrolimus dosing in pediatric renal transplant patients. The work focused on population pharmacokinetics of tacrolimus, a cornerstone immunosuppressive agent, to individualize dosing strategies. By quantifying how CYP3A5 status affects drug handling, the researchers aimed to improve the balance between efficacy and toxicity risks in a population where dosing variability is clinically challenging. The findings reinforce the role of pharmacogenomics in immunosuppressive management. For transplant programs, genetic-guided dosing could reduce the need for trial-and-error titration and improve stability of therapeutic drug exposure during early post-transplant care.